Latest News and Press Releases

Company reviews goals and significance of the clinical trial and outlines development and partnering strategy

Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease

ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...

Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.

Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.

Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...

Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...

ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...

ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...